Abstract:Activation of the cholecystokinin type B receptor (CCKBR) by cholecystokinin octapeptide (CCK-8) inhibits opioid analgesia. Chronic opiate treatment leads to an increase in the CCK-8 concentration and thus enhances the antagonism of CCK-8 against opioid analgesia; the underlying molecular mechanisms remain of great interest. In the present study, we validated the colocalization of the μ-opioid receptor (MOR) and CCKBR in pain signal transmission-related spinal cord dorsal horn and dorsal root ganglion neurons of rats. Co-immunoprecipitation (Co-IP) and fluorescence lifetime-imaging-microscopy-based fluorescence resonance energy transfer (FLIM-FRET) assays showed that MOR heteromerized with CCKBR directly in transfected HEK293 cells. Combined with MOR mutant construction, the third transmembrane domain of MOR (TM3MOR) was demonstrated to participate in heteromerization with CCKBR. Receptor ligand binding, ERK phosphorylation and cAMP assays showed that MOR heteromerization with CCKBR weakened the activity of MOR. A cell-penetrating interfering peptide consisting of TM3MOR and TAT (a transactivator of HIV-1) sequences from the N terminal to the C terminal disrupted the MOR–CCKBR interaction and restored the activity of MOR in transfected HEK293 cells. Furthermore, intrathecal application of the TM3MOR-TAT peptide alleviated CCK-8-injection-induced antagonism to morphine analgesia in rats. These results suggest a new molecular mechanism for CCK-8 antagonism to opioid analgesia in terms of G-protein-coupled receptor (GPCR) interaction through direct heteromerization. Our study may provide a potential strategy for pain management with opioid analgesics. A hormone known to weaken the pain-relieving effects of opioid drugs does so because of interaction between the hormone receptor and the opioid receptor. A team from Peking University in Beijing, China, led by Li Su and You Wan showed that an opioid receptor and a receptor that is activated by a peptide hormone involved in digestion are both found in rat neurons of the spinal cord and spinal ganglion. They demonstrated in human cells that the two receptors could form a single structural complex, and that this process weakened the ability of the opioid receptor to respond to drugs such as morphine. A decoy peptide that disrupted the interaction between the receptors boosted the analgesic effects of morphine in rats. Similar strategies could help with pain management.

Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation.

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

Synaptic Mechanism for Functional Synergism Between Δ- and Μ-Opioid Receptors

Synaptic mechanism for functional synergism between delta- and mu-opioid receptors.

Oligomerization of MrgC11 and Μ-Opioid Receptors in Sensory Neurons Enhances Morphine Analgesia.

Single-molecule detection of transient dimerization of opioid receptors 2: Heterodimer blockage reduces morphine tolerance

Heteromerization of Μ-Opioid Receptor and Cholecystokinin B Receptor Through the Third Transmembrane Domain of the Μ-Opioid Receptor Contributes to the Anti-Opioid Effects of Cholecystokinin Octapeptide

Disruption of Cdk5-Associated Phosphorylation of Residue Threonine-161 of the Delta-Opioid Receptor: Impaired Receptor Function and Attenuated Morphine Antinociceptive Tolerance

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

The μ-opioid receptor-mediated G i/o protein and β-arrestin2 signaling pathways both contribute to morphine-induced side effects

The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence

Coexpression of Delta- and Mu-Opioid Receptors in Nociceptive Sensory Neurons

Signaling Cascades for Δ-Opioid Receptor-Mediated Inhibition of GABA Synaptic Transmission and Behavioral Antinociception

Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors.

The Μ-Opioid Receptor-Mediated Gi/o Protein and Β-Arrestin2 Signaling Pathways Both Contribute to Morphine-Induced Side Effects

Molecular Recognition of Morphine and Fentanyl by the Human Μ-Opioid Receptor

Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents.

Modulation of mTOR Activity by μ‐Opioid Receptor is Dependent upon the Association of Receptor and FK506‐Binding Protein 12

Mu Opioid Receptor Heterodimers Emerge as Novel Therapeutic Targets: Recent Progress and Future Perspective

DAMGO-induced μ opioid receptor internalization and recycling restore morphine sensitivity in tolerant rat.

Mu-opioid receptor and receptor tyrosine kinase crosstalk: Implications in mechanisms of opioid tolerance, reduced analgesia to neuropathic pain, dependence, and reward